Real-world disease, patient characteristics and treatment patterns in patients with Non-Small Cell Lung Cancer and extensive stage Small cell lung cancer in Belgium [AIBED]

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  OSIMERTINIB

  DURVALUMAB
• Medical condition to be studied:
  Non-small cell lung cancer

  Small cell lung cancer

Population studied

• Short description of the study population:
  Non-small cell lung cancer and small cell lung cancer diagnosed between 1 January 2019 and 31 December 2021.
• Estimated number of subjects:
  2000

Study design details

• Study design:
  Multicenter study (n = 5) analyzing routinely collected data from pseudonymized electronic health records (EHRs) using natural language processing (NLP) for unstructured sources. The algorithm mapped variables to a standard terminology, generating OMOP CDM databases, validated per hospital.
• Main study objective:
  This study describes the following in Belgian patients with lung cancer for specific subpopulations of interest (Patients with stage IB-IIIB NSCLC, stage III unresected NSCLC, Stage IV NSCLC, or ES-SCLC):; • Demographics; • Biomarker testing with focus on EGFR and PD-L1; • Treatment patterns with focus on durvalumab and osimertinib
• Setting:
  Belgium, diagnosis between 2019 and 2021